Wilcox, Mark H. http://orcid.org/0000-0002-4565-2868
Article History
Received: 22 October 2019
Accepted: 28 November 2019
First Online: 27 January 2020
Competing interests
: M.H.W. has received research funding and/or consultancy funding from several companies developing CDI treatment/prevention therapeutics, including Astellas, Da Volterra, Merck, Pfizer, Sanofi-Pasteur, Seres, Summit, Synthetic Biologics, Valneva and Vaxxilon.
Free to read: This content has been made available to all.